Public Health Alert: NAFDAC Warns Against Falsified Gold Vision Oxytocin Injection

In a critical move to safeguard public health, the National Agency for Food and Drug Administration and Control (NAFDAC) has issued a nationwide alert regarding the circulation of a falsified and unregistered drug known as Gold Vision Oxytocin injection 10IU. The alert, dated Monday, August 25, 2025, was released after the product was discovered by the agency’s Post Marketing Surveillance (PMS) directorate during a risk-based sampling survey.

According to NAFDAC, the fake drug, with a falsified registration number A4-9566, is labeled as manufactured by Anhui Hongye Pharmaceutical Co., Ltd. in China and marketed by a local company in Enugu, Nigeria. The agency confirmed that the product is not present in its official database of registered medicines.

Oxytocin is a critical, life-saving medication primarily used in maternal healthcare. It is essential for inducing or strengthening labor contractions, controlling severe bleeding after childbirth (postpartum hemorrhage), and assisting in the management of incomplete or inevitable abortions.

The use of a falsified version of this critical drug poses a significant threat to the lives of mothers and newborns. NAFDAC warns that such counterfeit products may contain incorrect doses, no active ingredients, or even harmful contaminants. The administration of a poor-quality Oxytocin injection could lead to ineffective uterine contractions, which can result in severe, uncontrolled bleeding and, in the worst-case scenarios, maternal death.

NAFDAC has urged all importers, distributors, retailers, and healthcare professionals to exercise extreme caution within the supply chain. The public is advised to only procure medicines from authorized and licensed suppliers and to meticulously check the authenticity and physical condition of all products. The agency has also instructed its zonal directors and state coordinators to intensify surveillance and retrieve the falsified product from circulation. Healthcare professionals and consumers are encouraged to report any suspicion of substandard or falsified medicines to the nearest NAFDAC office or through its official communication channels.